PharmacyCodes



Metokurinjodid en es it fr

Metokurinjodid Brand names, Metokurinjodid Analogs

Metokurinjodid Brand Names Mixture

  • No information avaliable

Metokurinjodid Chemical_Formula

C23H31NO7

Metokurinjodid RX_link

http://www.rxlist.com/cgi/generic3/cellcept.htm

Metokurinjodid fda sheet

Metokurinjodid FDA

Metokurinjodid msds (material safety sheet)

Metokurinjodid Synthesis Reference

No information avaliable

Metokurinjodid Molecular Weight

469.955 g/mol

Metokurinjodid Melting Point

No information avaliable

Metokurinjodid H2O Solubility

Slightly soluble (43 mg/mL at pH 7.4)

Metokurinjodid State

Solid

Metokurinjodid LogP

2.424

Metokurinjodid Dosage Forms

Capsule (250mg); Tablet (500 mg); Powder for solution (200 mg/mL constituted)

Metokurinjodid Indication

For the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. CellCept should be used concomitantly with cyclosporine and corticosteroids.

Metokurinjodid Pharmacology

Mycophenolate mofetil is a prodrug of mycophenolic acid, an antibiotic substance derived from Penicillium stoloniferum. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase. Mycophenolic acid is important because of its selective effects on the immune system. It prevents the proliferation of T-cells, lymphocytes, and the formation of antibodies from B-cells. It also may inhibit recruitment of leukocytes to inflammatory sites.

Metokurinjodid Absorption

Rapidly absorbed following oral administration. In 12 healthy volunteers, the mean absolute bioavailability of oral mycophenolate mofetil relative to intravenous mycophenolate mofetil (based on MPA AUC) was 94%. Food (27 g fat, 650 calories) has no effect on the extent of absorption (MPA AUC) of mycophenolate mofetil.

Metokurinjodid side effects and Toxicity

Oral (LD50): Acute: 352 mg/kg [Rat], 1000 mg/kg [Mouse], and >6000 mg/kg [Rabbit]. Possible signs and symptoms of acute overdose could include the following: hematological abnormalities such as leukopenia and neutropenia, and gastrointestinal symptoms such as abdominal pain, diarrhea, nausea and vomiting, and dyspepsia.

Metokurinjodid Patient Information

No information avaliable

Metokurinjodid Organisms Affected

Humans and other mammals